Tag Archives: STALICLA

Spexis Provides Update Regarding Debt Restructuring Moratorium

BIOTECH

Stalicla Secures $17.4 Million in Series B Financing
January 16, 2024

Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders,...

Stalicla And Firefly Neuroscience Enter Partnership Agreement For The Development Of Electroencephalogram (eeg) As A Biomarker For Subgroups Of Patients With Asd

BIOTECH

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
March 27, 2023

STALICLA and Firefly Neuroscience enterPartnership Agreement for the Development of Electroencephalogram (EEG) asa Biomarker for Subgroups of Patients with...

Stalicla Signs Exclusive In Licensing Agreement For Late Stage Clinical Neuropsychiatric And Neurodevelopmental Disorder Treatment

BIOTECH

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
January 9, 2023

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines...

Stalicla Sa And Evgen Pharma Plc Ink $160.5m Licensingdeal For Sfx 01

BIOTECH

Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
October 12, 2022

Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders...

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.
Accept